Icatibant
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Icatibant: Serpinopathy with toxic serpin polymerization
One-Sentence Summary
Icatibant is a synthetic peptide that blocks bradykinin receptors and is marketed in Australia as an injection. The TxGNN model predicts it may be relevant to serpinopathy with toxic serpin polymerization. No clinical trials or publications in the data compiled for this report support this prediction, so it rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Serpinopathy with toxic serpin polymerization |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action text is not available for this report. The pharmacology data compiled for it show that icatibant is a peptide ligand acting at the bradykinin B1 and B2 receptors. Its established effect is to antagonise B2 receptor signalling.
Toxic serpin polymerization is a protein-misfolding, gain-of-function problem in which abnormal serpin proteins aggregate. Blocking bradykinin B2 receptors is not expected to act on that process. The high score most likely reflects a model-derived association with the serpin protein family rather than a shared mechanism. At this stage the prediction should be treated as a hypothesis without a supporting biological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1976B | Cipla Icatibant | Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe | Not available in the data compiled for this report |
One valid single-ingredient entry is recorded, and the product is currently marketed.
Safety Considerations
- Drug Interactions: The interaction data compiled for this report list 10 moderate-level interactions, all with ACE inhibitors: benazepril, captopril, enalapril, perindopril, trandolapril, moexipril, lisinopril, quinapril, ramipril and fosinopril. Co-prescribing with any of these needs clinical review.
No key warnings or contraindications are recorded in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported by a model score only (0.9999). There are no clinical trials or publications on this disease, and there is no plausible link between bradykinin B2 receptor blockade and toxic serpin polymerization. The evidence level is L5.
To proceed, the following is needed:
- Preclinical or mechanistic evidence that bradykinin receptor antagonism affects serpin polymerization or its downstream pathology
- Any published clinical or observational data in this disease
- Review of the TGA-approved Product Information for warnings, contraindications and the registered indication
- A defined patient population and safety plan, including review of ACE inhibitor co-prescribing, before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.